Loading...
•
Dec 31, 2023
Sotera Health Q4 2023 Earnings Report
Sotera Health reported Q4 2023 results with revenue increase driven by strong performance in Nordion and Sterigenics, offset by a slight decrease in Nelson Labs. Net income saw significant growth compared to the previous year due to a large legal reserve in 2022.
Key Takeaways
Sotera Health's Q4 2023 net revenues increased by 23.3% to $310 million compared to the same period last year. Net income was $39 million, a significant improvement from the net loss of $320 million in Q4 2022. Adjusted EBITDA increased by 28.7% to $167 million, and Adjusted EPS was $0.26, up by $0.01 per diluted share.
Net revenues for Q4 2023 increased by 23.3% to $310 million.
Net income for Q4 2023 was $39 million, compared to a net loss of $320 million in Q4 2022.
Adjusted EBITDA for Q4 2023 increased by 28.7% to $167 million.
Adjusted EPS for Q4 2023 was $0.26, an increase of $0.01 per diluted share.
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Revenue by Segment
Sterigenics Revenue
CapyFin.comNordion Revenue
CapyFin.comNelson Labs Revenue
CapyFin.com Forward Guidance
Sotera Health is providing its full-year 2024 outlook with net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%.
Positive Outlook
- Net revenues growth in the range of 4.0% to 6.0%.
- Adjusted EBITDA growth in the range of 4.0% to 6.0%.
- Tax rate applicable to Adjusted Net Income in the range of 31.5% to 34.5%.
- Adjusted EPS in the range of $0.67 to $0.75.
- Capital expenditures in the range of $205 million to $225 million.
Challenges Ahead
- Interest Expense in the range of $170 million to $180 million.
- Uncertainties caused by changes to the regulatory landscape.
- Restructuring items.
- Certain fair value measurements.
- Impact of inflationary trends including their impact on energy prices and the supply of labor.
Revenue & Expenses
Visualization of income flow from segment revenue to net income